Entrada Therapeutics (TRDA) Cash from Financing Activities (2020 - 2026)
Entrada Therapeutics (TRDA) recorded quarterly Cash from Financing Activities of $100000.0 in Q1 2026, down 47.92% quarter-over-quarter from $192000.0 in Q4 2025, and down 71.43% on a YoY basis from $350000.0 in Q1 2025.
Entrada Therapeutics (TRDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 71.43% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $637000.0 (down 99.38% YoY), while the FY2025 annual figure was $887000.0, down 99.14% from the prior year.
- Cash from Financing Activities was $100000.0 for Q1 2026 at Entrada Therapeutics, down from $192000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $101.4 million in Q2 2024 to a low of -$11000.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $7.4 million across 5 years, with a median of $337000.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 38972.0% in 2023, then plunged 102.99% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $358000.0 in 2022, then surged by 92.74% to $690000.0 in 2023, then soared by 103.19% to $1.4 million in 2024, then plunged by 86.31% to $192000.0 in 2025, then tumbled by 47.92% to $100000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $100000.0 (Q1 2026), $192000.0 (Q4 2025), and $8000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 337,000.00 |
| Jun 30, 2025 | 337,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | -11,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 101.37 Mn |
| Jun 30, 2024 | 101.37 Mn |
| Mar 31, 2024 | 206,000.00 |
| Mar 31, 2024 | 206,000.00 |
| Dec 31, 2023 | 690,000.00 |
| Dec 31, 2023 | 690,000.00 |